GlassScriptPhysician profile
Minh Le
NPI 1508252180
$3,924.33
in general payments reported to CMS, 2019-2025
25 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $248 · 2022: $691 · 2023: $893 · 2024: $920 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,780 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,780.30 |
| Education | $204.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,583.95 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $379.89 | 2022-2025 | Breztri, Tezspire, Airsupra |
| Mylan Specialty L.P. | $261.98 | 2023-2024 | Yupelri |
| Genzyme Corporation | $249.44 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.52 | 2022-2025 | Ofev |
| Amgen INC. | $191.71 | 2022-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $147.81 | 2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $141.50 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Verona Pharma, INC. | $81.55 | 2025 | Ohtuvayre |
| Sk Life Science, INC. | $77.36 | 2024-2025 | |
| Philips North America LLC | $64.70 | 2024-2025 | Vest Therapy Und, (8874) Incourage |
| Teva Pharmaceuticals USA, INC. | $57.44 | 2022-2023 | Austedo, Airduo Digihaler |
| Genentech USA, INC. | $56.07 | 2023-2025 | Xolair |
| Insmed, INC. | $53.91 | 2025 | Arikayce, Brinsupri |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $45.58 | 2024 | Prolastin-C Liquid |
| Ucb, INC. | $28.78 | 2024 | Briviact |
| Medtronic, INC. | $26.51 | 2025 | Illumisite |
| Baxter Healthcare | $26.05 | 2023 | Hillrom - Life 2000 Ventilation System |
| Avanir Pharmaceuticals, INC. | $24.97 | 2022 | |
| Electromed, INC. | $20.75 | 2023 | Smartvest |
| Janssen Pharmaceuticals, INC | $18.61 | 2024 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $14.60 | 2022 | |
| Lilly USA, LLC | $14.08 | 2025 | Kisunla |
| Bayer Healthcare Pharmaceuticals INC. | $12.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minh Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.